The US Food and Drug Administration (FDA) has approved Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab-cwvz) to treat adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+ ...

NMOSD causes severe ocular effects, including optic neuritis, leading to vision loss and impacting quality of life. Early ...

Approximately 80% of all patients with NMOSD test positive for anti-AQP4 antibodies. During the phase 3 trial, MRI imaging was conducted on the spinal cord, optic nerve, and brain/brain stem to ...

Relevance of AQP4 Antibodies in Neuromyelitis Optica The discovery of AQP4-Ab, a serum marker of autoimmune neuromyelitis optica, has implications for our understanding of the pathogenesis of NMO ...